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A characterization of the B14R gene from Vaccinia virus (VACV) strain Western Reserve (WR) is
presented. Computational analyses of the B14R gene indicated high conservation in
orthopoxviruses but no orthologues outside the Poxviridae. To characterize the B14 protein, the
B14R gene was expressed in Escherichia coli and recombinant protein was purified and
used to generate a rabbit polyclonal antiserum. This antiserum recognized a 15 kDa cytoplasmic
protein in mammalian cells that were transfected with the B14R gene or infected with VACV WR,
but not from cells infected with a VACV mutant (vDB14) from which the B14R gene was deleted.
Compared to wild-type and revertant virus controls, vDB14 had normal growth kinetics in cell
culture. The virulence of vDB14 was assessed in two in vivo models. Mice infected intranasally
with vDB14 had similar weight loss compared to the controls, but in C57BL/6 mice infected
intradermally vDB14 induced a smaller lesion size compared with controls. Moreover, intradermal
infection with vDB14 caused an increased infiltration of cells into the infected lesion despite
the smaller lesion size. Therefore, B14 is an intracellular protein that is non-essential for virus
replication in cell culture but contributes to virus virulence in vivo and affects the host response
to infection.
INTRODUCTION
Vaccinia virus (VACV) is a member of the genus Orthopox-
virus of the Poxviridae, a family of large, dsDNA viruses
replicating in the cytoplasm (Moss, 2001). The VACV strain
Copenhagen genome (191 kb) was predicted to encode
around 200 genes (Goebel et al., 1990) and the central region
of the genome (~100 kb), like that of other chordopox-
viruses, is highly conserved and contains 90 genes that are
present in all sequenced chordopoxviruses (Upton et al.,
2003; Gubser et al., 2004). Most of these genes encode
proteins with essential functions for virus replication. In
contrast, genes located in the terminal regions are more
variable and encode proteins that are non-essential for virus
replication but which affect virus virulence, host range and
modulation of the host response to infection (Smith &
McFadden, 2002). Immunomodulators from VACV and
other poxviruses may act inside or outside the infected cell
and may block the action of cytokines, chemokines and
interferons, or intracellular signalling pathways leading to
apoptosis or gene activation (Seet et al., 2003).
The B14R gene of VACV strain Western Reserve (WR) is
located in the right terminal region that is rich in immuno-
modulators. For instance, the upstream gene encodes an
intracellular protein that inhibits caspase-1 activity and
thereby induction of apoptosis (Dobbelstein & Shenk, 1996;
Kettle et al., 1997) and the downstream gene encodes a
soluble interleukin (IL)-1b-binding protein (Alcami &
Smith, 1992; Spriggs et al., 1992) that inhibits development
of fever during systemic infection (Alcami & Smith, 1996).
VACV strain WR B14R gene is predicted to encode a 149 aa
protein (Howard et al., 1991; Smith et al., 1991). The
equivalent gene in VACV strain Copenhagen is called B15R
due to disruption of the preceding open reading frame
(ORF) into fragments called B13R and B14R (Goebel et al.,
1990). Unusually for a gene located in a terminal region
of the genome, VACV WR B14R gene is highly conserved
among different orthopoxviruses, suggesting an important
function (Gubser & Smith, 2002; Gubser et al., 2004).
Although the B14R gene is conserved, hitherto there has
been no characterization of the encoded protein or func-
tional analysis with viruses lacking this gene. We selected the
B14R gene for study as part of our ongoing interest in VACV
immunomodulatory proteins because of its location and
conservation.
In this study, we identified the B14 protein in infected cells
using specific antiserum, and constructed a VACV mutant
lacking the B14R gene (vDB14) and a revertant in which the
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gene was reinserted into the deletion mutant (vB14-rev).
The mutant virus was compared in vitro and in vivo to the
wild-type (vB14) and revertant (vB14-rev) controls. Data
presented show that although B14 is non-essential for virus
replication in cell culture, it promotes VACV virulence in a
murine intradermal (i.d.) model (Tscharke & Smith, 1999;
Tscharke et al., 2002; Reading & Smith, 2003) and influences
the infiltration of cells into the infected lesion. As such, it
represents another intracellular virulence factor that is also
an immunomodulator. Its mechanism of action is under
investigation.
METHODS
Cell culture. Rabbit kidney RK13 cells, African green monkey kidney
cells BS-C-1 and CV-1 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% heat-inactivated
fetal bovine serum (FBS) (Harlan Sera-Lab), 50 IU penicillin (Gibco-
BRL) ml21, 50 mg streptomycin (Gibco-BRL) ml21 and 2 mM L-
glutamine (Gibco-BRL). HeLa cells were purchased from the
European Collection of Cell Cultures.
Construction of plasmid vectors. Wild-type or modified B14R
gene fragments were produced by PCR using VACV WR genomic
DNA as template and were then cloned into pSJH7 (Hughes et al.,
1991) via EcoRI and XbaI restriction sites. To produce plasmid
pDB14, a DNA fragment containing the left and right flanking
regions of the B14R gene but lacking the entire B14R ORF was pro-
duced by overlapping PCR. The 59 fragment was generated with
oligonucleotides 59-GGAATTCCTTCGGTTCAACTGGAGATTA-39
(L-FA), containing an EcoRI restriction site (underlined) and 59-
AAATGTCAAGATGTACAACCTTACCAATTGCAATTGGAA-39, con-
taining nucleotides from the 39 fragment (italics) at the 59 end. The
39 fragment was generated with oligonucleotides 59-GTTGTACAT-
CTTGACATTT-39, complementary sequence to the 59 fragment and
59-GCTCTAGAGCATTGCTACCATTATCTATC-39 (R-FB), contain-
ing an XbaI restriction site (underlined). Based on the overlapping
region, these two fragments were joined by PCR using the L-FA and
R-FB oligonucleotides to become an FA–FB fragment. To generate
pB14-rev, a DNA fragment containing the entire B14R gene and
flanking regions was generated with oligonucleotides FA and FB. To
construct a C-terminal haemagglutinin (HA)-tagged B14 VACV
(vB14-HA), two fragments were generated and then joined by
overlapping PCR. The first fragment was produced by PCR with
oligonucleotides L-FA and 59-AACATCGTATGGGTACATATTC-
ATACGCCGGAATATGA-39, encoding part of an HA peptide DNA
sequence (italics). The second fragment was amplified by PCR with
oligonucleotides R-FB and 59-ATGTACCCATACGATGTTCCAGA-
TTACGCTTGATGAGTTGTACATCTTGA-39, containing the entire
HA peptide DNA sequence (italics). These two fragments were joined
with the L-FA and R-FB to become pSJH7-B14-HA.
To express the wild-type B14 protein and B14 tagged at the C terminus
with HA in mammalian cells, DNA fragments were generated by PCR
using pSJH7-B14-HA as template. For wild-type B14 expression (pCI-
B14), a DNA fragment containing the B14R gene was produced by PCR
with oligonucleotides 59-GGAATTCCATGACGGCCAACTTTAGTA-
CC-39 (L-B14), containing an EcoRI restriction site (underlined) and
59-GCTCTAGAGCTCATCAATTCATACGCCGGAA-39, containing an
XbaI restriction site (underlined). For expression of C-terminal HA
tagged B14 (pCI-B14-HA), a DNA fragment encoding the HA peptide
fused to the 39 end of B14R gene was generated by PCR with
oligonucleotides L-B14 and 59-GCTCTAGAGCTCATCAAGCGTAA-
TCTGGAAC-39, containing XbaI restriction site (underlined) and
nucleotides for the HA peptide (italics). These two fragments were
cloned into the pCI vector (Promega) by EcoRI and XbaI restriction
sites to become pCI-B14-HA. The fidelity of the PCR-derived regions
from all plasmids was verified by DNA sequencing.
Construction of recombinant viruses. A VACV deletion mutant
lacking the B14R gene coding sequences (vDB14), a revertant virus
with these sequences reintroduced (vB14-rev) and a virus containing
a B14R gene encoding a C-terminal HA-tag (vB14-HA) were con-
structed. The modified and wild-type B14R gene were inserted into
plasmid pSJH7 (Hughes et al., 1991), containing the E. coli guanine
xanthine phosphoribosyltransferase gene as a selectable marker (Boyle
& Coupar, 1988). The plasmids were then transfected into either
VACV WR-infected CV-1 cells (to make vDB14) or vDB14-infected
cells (to make vB14-rev and vB14-HA), and recombinant viruses
were isolated by transient dominant selection (Falkner & Moss,
1990).
Immunoblotting. Transfected or infected cells were lysed and pre-
pared for immunoblotting as described previously (Parkinson &
Smith, 1994).
Immunofluorescence. Cells used for fluorescent and confocal
microscopy were grown on sterilized glass coverslips (borosilicate
glass; BDH) in six-well plates. The cells were washed three times in
ice-cold PBS, fixed in 4% paraformaldehyde in PBS for 1 h at room
temperature and incubated with 0?1% Triton X-100 (Sigma) for
10 min at room temperature. The samples were blocked with 10%
FBS in PBS for 1 h at room temperature (or 4 uC overnight), incu-
bated with primary antibody (Ab) at room temperature for 1 h
and washed three times in PBS. Samples were then incubated with
fluorescein isothiocyanate- or tetramethylrhodamine isothiocyanate-
conjugated secondary Ab at room temperature for 1 h, washed
three times with PBS and mounted in Mowiol-4’,6-diamidino-2-
phenylindole medium. Samples were examined with a Zeiss 512
laser scanning confocal microscope and images were reconstructed
and processed using Confocal Assistant and Adobe Photoshop
software.
Virus growth curves. Monolayers of BS-C-1 or CV-1 cells were
infected with either 10 or 0?01 p.f.u. per cell for measurement of
one-step or multi-step growth kinetics, respectively. The culture
supernatant was removed at the indicated times and centrifuged at
800 g at 4 uC for 10 min to collect detached cells. Attached cells were
scraped into DMEM/2?5% FBS, added to the cells collected from
the supernatant, frozen and thawed three times and sonicated to
obtain the cell-associated virus. Infectious virions were determined
by plaque assay on duplicate BS-C-1 cell monolayers.
Virulence assays. For murine intranasal (i.n.) models, female
BALB/c mice (5–6 weeks old) were anaesthetized and infected intra-
nasally with the indicated viral dosage in 20 ml PBS (Williamson
et al., 1990). For the murine i.d. model, female C57BL/6 mice
(6–8 weeks old) were anaesthetized and injected intradermally in the
left ear pinnae with either 104 p.f.u. per 10 ml PBS per ear as
described previously (Tscharke & Smith, 1999).
Analysis of cell populations in infected ears by flow cytometry.
At the indicated times, intradermally infected mice were sacrificed
and ears were removed. The infiltrate was collected and analysed as
described previously (Reading & Smith, 2003; Jacobs et al., 2006).
Briefly, cells in the i.d. compartment migrated into RPMI 1640
medium (Gibco-BRL) containing 50 IU penicillin (Gibco-BRL)
ml21, 50 mg streptomycin (Gibco-BRL) ml21, 10% FBS and 2?5 mM
HEPES, pH 7?4 in a plastic plate. Adherent and non-adherent cells
were pooled, washed once with RPMI/10% FBS, once with Tris/
NH4Cl buffer (0?14 M NH4Cl in 17 mM Tris, pH 7?2) and twice
with FC buffer (0?1% BSA, 0?1% NaN3 in PBS). Dermal cells were
identified by the staining of surface markers: CD3 [phycoerythrin
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(PE) anti-CD3; Becton Dickinson] on T lymphocytes, Ly6-G (PE
anti-Ly6-G; Becton Dickinson) on neutrophils and F4/80 (tri-color-
anti-F4/80; Caltag Laboratories) on macrophages.
Statistical analysis. Student’s t-test (two tailed, unpaired) was
used to examine the significance of raw data.
RESULTS
Computational analysis of the B14 protein
The VACV WR B14R gene (GenBank accession no.
AAO89475) was predicted to encode a 17?3 kDa protein
(Howard et al., 1991; Smith et al., 1991) without a trans-
membrane domain or a secretory signal peptide (see www.
poxvirus.org). Computational comparisons detected no
orthologues outside poxviruses but found very similar
proteins predicted to be encoded by many orthopoxviruses
including other VACV strains, Variola virus, Camelpox
virus, Monkeypox virus, Ectromelia virus and Cowpox
virus with 94–98% amino acid identity. The phylogenetic
relationships of these proteins are shown in a rooted tree
(Fig. 1, group I) produced from the aligned amino acid
sequences. Another group of more distantly related ortho-
poxvirus proteins, typified by protein B22 from VACV
Copenhagen, was identified and had between 41 and 42%
amino acid identity and between 57 and 61% amino acid
similarity (Fig. 1, group II). In some other chordopoxvirus
genera, e.g. Yatapoxvirus, Capripoxvirus, Leporipoxvirus and
Suipoxvirus, there are proteins related to B14 that have
between 30 and 41% amino acid identity and between 49
and 63% amino acid similarity (Fig. 1 group III). However,
these proteins clustered more closely with group II proteins
from orthopoxviruses than with B14 and the group I
proteins. For additional analysis of this family of protein
see www.poxvirus.org. The B14 family is part of Poxvirus
A4/B15 family (PF06225) and, interestingly, proteins related
to B14 are not found in the genera Avipoxvirus andMollusci-
poxvirus (see www.sanger.ac.uk/Software/Pfam).
The generation of B14R mutant VACV-WR
To study the function of B14 protein in virus-infected cells
several recombinant viruses were constructed based on
VACV strain WR (Methods). These included a plaque-
purified wild-type (vB14), deletion mutant (vDB14),
revertant (vB14-rev) and HA-tagged B14 (vB14-HA). The
genomes of these viruses were analysed by PCR and
restriction enzyme digestion using DNA extracted from
purified intracellular mature virus (IMV) (see Supple-
mentary Fig. S1 and S2 available in JGV Online). PCR using
primers for the B14R gene locus confirmed the presence of
the B14R gene in vB14, vB14-rev and vB14-HA and its
absence in vDB14 (Supplementary Fig. S1 available in JGV
Online). Digestion of genomic DNA with SphI showed
similar fragments for all viruses, except that a fragment of
approximately 3 kb was reduced in size by 500 bp in vDB14
compared with controls (Supplementary Fig. S2 available in
JGV Online), consistent with the loss of the B14R coding
sequences. Similar analysis with enzymes HindIII and SalI
found no differences outside the B14R locus (data not
shown).
Identification of B14 expression using
polyclonal antiserum
To identify the B14 protein in mammalian cells, the B14R
gene was expressed in E. coli with an N-terminal His-tag and
the recombinant protein was purified by Ni2+-affinity
column (data not shown) and used to raise a rabbit anti-B14
polyclonal Ab. Immunoblot analysis using this Ab identified
a 15 kDa protein in extracts of cells transfected with a
plasmid containing the B14R ORF driven by the human
cytomegalovirus immediate-early promoter (Fig. 2a) and in
cells infected by VACV WR (Fig. 2b). The specificity of the
Ab was confirmed by its recognition of the 15 kDa protein
(i) only in cells transfected with the B14R ORF but not the
empty vector, and (ii) in cells infected with wild-type and
revertant viruses but not vDB14 (Fig. 2b, lower panel). The
protein was not detected in highly purified VACV IMV
virions or in the tissue culture supernatant (data not
shown). The B14 protein was also expressed in mammalian
cells with an HA-tag fused to the C terminus. This protein
was recognized by an anti-HA monoclonal antibody (mAb)
and by the anti-B14 Ab, whereas the wild-type protein was
recognized only by the latter (Fig. 2a). To determine the
time of expression of B14 protein during VACV infection,
Fig. 1. A rooted phylogenetic tree of VACV WR B14 and
related poxvirus proteins. The sequences of the individual pro-
teins were aligned using program CLUSTAL W and a rooted tree
was derived from this alignment using PHYLIP (phylogeny infer-
ence package, version 3.2) via Biology WorkBench 3.2 website
(see http://workbench.sdsc.edu/). The bootstrap values from
1000 replica samplings are indicated. See www.poxvirus.org for
details of B14 protein related proteins.
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cells were infected in the presence or absence of cytosine
arabinoside (AraC), an inhibitor of viral DNA replication
and late protein expression, and extracts of cells were pre-
pared at different times post-infection (p.i.) and were then
analysed by immunoblotting (Fig. 2c). B14 was detected
from 2 h p.i., and at all times examined, and was present at
higher levels at 8 h p.i. It was still detected in cells in the
presence of AraC, indicating the protein was made during
the early phase of infection. In contrast, AraC blocked the
expression of D8, a protein known to be expressed late in the
VACV life cycle (Niles & Seto, 1988).
The location of the B14 protein was examined in HeLa cells
transfected with the plasmid encoding the HA-tagged B14
protein. Immunofluorescence analysis with the anti-HA
mAb and anti-B14 Ab detected a diffuse cytoplasmic stain-
ing with no obvious co-localization to specific organelles
or the cell surface and with relatively little staining in the
nucleus (Fig. 3a, upper panels). Only a weak background
signal was detected by pre-immune rabbit serum in the HA-
tag-positive transfected cells (Fig. 3a, lower right panel).
This indicated the specificity of anti-B14 Ab. To compare
the location of B14 in transfected cells with those infected by
VACV, at 8 h p.i. vB14-infected cells were stained with the
rabbit Ab and this detected a similar intracellular distribu-
tion (Fig. 3b, upper right panel). In vDB14-infected cells,
the B14 Ab showed very little staining (Fig. 3b, lower right
panel). The infection with both viruses was confirmed using
a mAb against the VACV D8 protein that detects punctate
cytoplasmic structures (Fig. 3b, left panels) that are virions
as reported previously (van Eijl et al., 2002; Carter et al.,
2003).
B14 is non-essential in cell culture
The role of B14 protein in the life cycle of VACV-WR was
examined by characterizing the phenotype of vDB14 in cell
culture. The plaque size formed by vDB14 was smaller than
that formed by vB14 and vB14-rev in CV-1 cells and slightly
smaller in BS-C-1 but not in RK13 cells (Fig. 4). The reduc-
tion in plaque size of CV-1 cells and BS-C-1 was 40 and
20%, respectively (n=20 plaques; P<0?05, Student’s t-test).
To examine the effect of B14 on the viral life cycle in more
detail in vitro, one-step (Fig. 5a) and multi-step (Fig. 5b)
growth curves were studied in BS-C-1 and CV-1 cells
(Supplementary Fig. S3 available in JGV Online). In both
cell types vDB14 showed similar growth kinetics to control
viruses after high (10 p.f.u. per cell) or low multiplicity
(0?01 p.f.u. per cell) of infection. Therefore, the basis for the
cell type-specific plaque size reduction in BS-C-1 and CV-1
cells was not a reduced virus yield.
B14 affects virus virulence and the recruitment
of leukocytes
The virulence of vDB14 was compared to control viruses in
two murine models. In an i.n. model, no significant differ-
ence in weight loss or signs of illness (data not shown) was
observed in animals infected with vDB14 at 104 or
Fig. 2. Characterization of B14 by immunoblotting. (a) Wild-
type and C-terminal HA-tagged B14 were expressed transiently
in HeLa cells. At 24 h post-transfection, extracts of cells were
prepared using RIPA buffer (20 mM Tris/HCl, pH 8?0, 150 mM
NaCl, 1% Nonidet P-40, 1% SDS) and analysed by immuno-
blotting with either rabbit anti-B14 Ab (left) or an anti-HA mAb
(right). (b) HeLa cells were infected by the indicated VACVs at
10 p.f.u. per cell for 16 h, or mock infected or transfected with
pCI-B14 for 24 h. The cells were lysed in RIPA buffer and
extracts were analysed by immunoblotting with anti-D8 mAb
(top panel) or anti-B14 Ab (lower panel). (c) HeLa cells were
infected with VACV WR at 10 p.f.u. per cell in the presence
(+) or absence (”) of 40 mg AraC ml”1. At the indicated times
p.i., the cells were washed once with PBS and lysed by addi-
tion of 200 ml protein loading buffer. Each cell lysate (20 ml)
was resolved by SDS-PAGE and analysed by immunoblotting
with anti-D8 mAb (top panel) or anti-B14 Ab (lower panel).
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36103 p.f.u. compared to control viruses (see Supplementary
Fig. S4 available in JGV Online). However, in an i.d. infec-
tionmodel, vDB14 induced a significantly (P<0?05) smaller
lesion size from days 6 to 17 p.i. (Fig. 6a). Measurement
of infectious virus in infected lesions indicated that
although the titres of infectious virus increased equally up
to 2 days p.i., thereafter (days 5 and 7) titres were reduced in
vDB14-infected ear lobes compared with controls (Fig. 6b).
These observations indicate that B14 enhances virus virul-
ence, at least partly by restricting clearance of virus.
To start to address the mechanism by which B14 affects the
outcome of infection in vivo, the cells in the infected ears
were extracted, quantified by trypan blue exclusion and
identified by flow cytometry (Methods). This revealed a
statistically (P<0?05) higher number of cells in vDB14-
infected ears at day 11 p.i. compared with tissue infected by
control viruses (Fig. 7a). Interestingly, in vDB14-infected
cells at day 8 p.i., neutrophils represented a reduced per-
centage of the total cell population compared with controls
(Fig. 7b), while the percentage of macrophages (Fig. 7c) and
lymphocytes (Fig. 7d) were slightly higher than the controls.
However, when the absolute number of each cell type was
analysed, rather than the percentage of total cells, the
number of macrophages (Fig. 7f) and T cells (Fig. 7g) were
significantly higher in ears infected by vDB14 than in ears
infected by controls on day 8 p.i. By this criterion the
number of neutrophils was not significantly different
between the groups (Fig. 7e). In addition, CD4, CD8,
T-cell receptor cd cells were also examined but showed no
significant difference (data not shown). Therefore, the
decrease in percentage of neutrophils on day 8 was likely to
be attributable to the corresponding increase of macro-
phages and lymphocytes. A similar result was observed on
day 5 p.i. when cells were extracted from ears by digestion
with collagenase (Jacobs et al., 2006) (data not shown).
Fig. 3. Subcellular localization of B14. (a) B14 with a C-terminal
HA tag was expressed transiently by transfection in HeLa cells
for 24 h. Cells were fixed and permeabilized as described in
Methods and stained with anti-HA mAb (left panels), anti-B14
Ab (top right panel) or rabbit pre-immune serum Abs (bottom
right panel). (b) HeLa cells were infected with vB14 (top
panels) or vDB14 (lower panels) at 10 p.f.u. per cell for 8 h.
Cells were fixed and permeabilized as in (a) and stained with
either anti-D8 mAb (left panels) or anti-B14 Ab (right panels).
Fig. 4. Plaque formation by vDB14. Monolayers of CV-1, RK13
or BS-C-1 cells were infected by vB14, vDB14 or vB14-rev
and overlaid with DMEM/2?5% FBS/1% carboxymethyl cellu-
lose. After 48 (CV-1 and BS-C-1 cells) or 72 h (RK13 cells),
the monolayers were stained with 0?1% crystal violet in 15%
ethanol and photographed.
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DISCUSSION
This paper provides a characterization of the B14 protein of
VACV strain WR that was uncharacterized hitherto. Data
presented show that B14 is an intracellular, 15 kDa protein
that is expressed early during infection and is non-essential
for the viral life cycle. Loss of the B14 protein reduced virus
virulence in a murine i.d. but not i.n. model. The attenua-
tion was manifested by a decrease in lesion size, reduced
virus titres and enhanced recruitment of macrophages and
T cells. Collectively, this indicates that B14 is an intracellular
immunomodulator.
In both infected and transfected cells B14 was predomi-
nantly cytoplasmic, indicating that other VACV proteins do
not influence the location of this protein. Under the con-
ditions examined, there was no apparent co-localization
with specific organelles, although a weak nuclear staining
was also apparent. Active nuclear import is dependent on
a nuclear localization signal or carrier protein(s) such as
importin that shuttle between the cytoplasm and nucleus.
Alternatively, small proteins (less than 20–40 kDa) could
pass through nuclear pores by passive diffusion (Macara,
2001; Xu & Massague, 2004). Therefore, the presence of
some B14 in the nucleus might be via an unknown active
transport system or simply by passive diffusion into the
nucleus due to the small molecular mass of B14.
B14 is a non-essential protein based on in vitro character-
ization of vDB14. Although the mutant displayed reduced
plaque size compared with wild-type and revertant control
viruses in BS-C-1 and CV-1 cells, the plaque formed by each
virus was indistinguishable in size in RK13 cells. However,
vDB14 failed to show a significant decrease in growth
Fig. 5. Growth kinetics of vDB14. BS-C-1 cells were infected
at either 10 (a) or 0?01 (b) p.f.u. per cell and aliquots of
infected cells were collected at the indicated times p.i. Cells
were frozen and thawed three times, sonicated and the virus
infectivity was titrated in duplicate on BS-C-1 cell monolayers.
Data are presented as the mean log10 p.f.u.±SD.
Fig. 6. Virulence assay in murine i.d. model. (a) Female
C57BL/6 mice (n=6) were infected i.d. with 104 p.f.u. of the
indicated viruses and the size of the lesion was measured daily
with a micrometer. Horizontal bar indicates the days on which
the lesion size caused by vDB14 was statistically different
(P<0?05) from both vB14 and vB14-rev. Data are means of
lesion size±SD. (b) Infectious virus in infected lesions. Mice
were infected in both ears as in (a) and at the indicated time
p.i. the animals were sacrificed, ears were removed and infec-
tious virus was determined by plaque assay on duplicate mono-
layers of BS-C-1 cells. Asterisks indicate days on which the
titre of virus present in ears infected with vDB14 was signifi-
cantly different from both vB14 and vB14-rev-infected tissue.
Data are means of viral titres±SD.
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kinetics, even in BS-C-1 and CV-1 cells. The major factor
determining plaque size is the ability to form virus-tipped
actin tails beneath cell-associated enveloped virus particles
at the cell surface that drive surface virions into surrounding
cells, for review see Smith et al. (2002). However, an analysis
of actin-tail formation in cells infected by vDB14 showed no
difference from controls (data not shown). Other VACV
proteins affect the plaque size or morphology without
inhibiting actin-tail formation. For instance, a VACV strain
lacking kelch-like protein C2 produced plaques with a
distinct morphology but the same size (Pires de Miranda
et al., 2003) and either the deletion (Parkinson et al., 1995)
or overexpression (Sanderson et al., 1996) of the A38 protein
reduced plaque size. Overall, B14 is not required for the
virus replication and the basis for the restricted plaque size is
not due to a cell-line-specific defect in viral growth or
inability to form any actin tails.
In vivo analysis showed that B14 contributed to virus virul-
ence in a murine i.d. (local infection) but not i.n. (systemic
infection) model. Previously, other VACV immunomodu-
lators were shown to exhibit a phenotype in either one
model or the other and this may be explained by the
different inflammatory responses following infection with
VACV via the i.n. and i.d. routes (Tscharke et al., 2002;
Reading & Smith, 2003). Analysis of infectious virus titres in
infected dermal tissue showed that by 2 days p.i. the virus
titres had increased for all viruses to a similar extent;
therefore, there was no replicative defect associated with loss
of B14 in vivo. However, subsequently (days 5 and 7 p.i.) the
titres of virus in ears infected with vDB14 was reduced
compared with controls. This finding indicated that B14
impaired the ability of the host response to control virus
growth, and so in its absence smaller lesions were produced.
To examine the effect of B14 in vivo further, cells that were
present in the infected lesions were extracted and analysed
by staining with specific mAb and FACS analysis. Although
there was a trend showing an increased infiltration of
cells into the vDB14-infected ears on days 5 and 8 p.i. this
was only significantly different from controls at day 11 p.i.
The absolute number of neutrophils present in infected
lesions was not altered at any time point, but the number
of macrophages and T cells rose significantly at day 8 p.i.
in vDB14-infected lesions compared with controls. This
increase in leukocytes indicates an enhanced host inflam-
matory response in the absence of B14, and may contribute
to the size restriction and early resolution of the resulting
lesion.
The recruitment of leukocytes to the skin is dependent on
the expression of chemokines and cytokines (Gillitzer &
Goebeler, 2001; Schon et al., 2003). Among these mediators,
chemokines CCL2 and CCL3 (formerly monocyte chemoat-
tractant protein-1 and macrophage inflammatory protein-
1a, respectively) play important roles in recruiting T cells
and macrophages (Kunstfeld et al., 1998; von Stebut et al.,
2003). Therefore, the production of such chemokines early
after infection will affect the cellular infiltrate. Infection by
vDB14 caused a greater infiltrate in infected tissues on days
5–11 p.i. compared with infection by control viruses
(although this was only significantly different on day 11).
Notably these infiltrates contained increased numbers of
T cells and macrophages (day 8 p.i.). Taken together, these
findings suggest that B14 may modulate the inflammatory
responses, possibly by affecting the expression of pro-
inflammatory chemokines such as CCL2 and CCL3.
However, the mechanism by which B14 exerts such
immunomodulation remains to be investigated.
Fig. 7. Characterization of infiltrating leukocytes in the C57BL/
6 mice infected intradermally with 104 p.f.u. of the indicated
viruses. Cells were extracted (Methods) from both ears of an
infected mouse and pooled. (a) Total numbers of viable cells
were determined by trypan blue exclusion. Data are means of
cell counts±SD. In these cells, neutrophils (b), macrophages
(c) and T cells (d) were identified by corresponding surface
markers as described in Methods. The absolute number of neu-
trophils (e), macrophages (f) and T cells (g) at days 8 and 11
p.i. were determined as described in Methods. The mean±SD
of data from three infected mice were analysed. Asterisks
indicate the day on which data for vDB14 are significantly
different from the vB14 and vB14-rev groups (P<0?05,
Student’s t-test).
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In summary, B14 is an intracellular virulence factor that is
highly conserved in orthopoxviruses and modulates the
host response to infection. These findings contribute to our
understanding of poxvirus pathogenesis and suggest a
means by which attenuated orthopoxvirus vaccines may be
produced.
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